CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula,

Moderna has withdrawn the BLA for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after consulting with FDA.

T he U.S. Centers for Disease Control and Prevention (CDC) is no longer recommending the COVID-19 vaccine for pregnant women and healthy children, the U.S. Secretary of Health and

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference,